Long acting GLP-1 receptor agonist (injectable)
Dulaglutide 0.5 mg injection once weekly
DULA_SC_0p5MG_QW
Related
- All doses pooled: Dulaglutide injection
- Dulaglutide 1.0 mg injection once weekly
- Dulaglutide 1.5 mg subcutaneous once weekly
- Dulaglutide 3.0 mg subcutaneous once weekly
- Dulaglutide 4.5 mg subcutaneous once weekly
- Dulaglutide 0.25 mg injection once weekly
- Dulaglutide 0.75 mg subcutaneous once weekly
- Dulaglutide flexible dose injection once weekly
- Dulaglutide 2.0 mg injection once weekly
- Dulaglutide 0.1 mg injection once weekly
- Dulaglutide 0.75 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.45 (0.01 to 22.61) | 0.48 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.04 (0.08 to 10.47) | 0.57 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.64 (0.05 to 4.01) | 0.61 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.93 (0.07 to 7.99) | 0.63 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.20 (0.72 to 6.02) | 0.56 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.74 (0.06 to 5.08) | 0.76 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.40 (0.37 to 4.59) | 0.55 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.89 (0.14 to 3.80) | 0.67 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.63 (0.01 to 49.51) | 0.62 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.84 (0.05 to 12.74) | 0.47 |
Trials
- NCT01001104Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Japanese Patients With Type 2 Diabetes2009 · 145 randomized · 12 weeks
- NCT00791479Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions2008 · 167 randomized · 12 weeks